100 Results Way
Fax: 1-877-295 -8102
About GE Healthcare
GE Healthcare Life Sciences
The Life Sciences business of GE Healthcare exists to enable and accelerate molecular and precision medicine. We do this by helping our customers discover, make and use new medicines.
Healthcare needs more precise diagnoses and treatments to improve patient outcomes, address the globally rising incidence of lifestyle and chronic diseases, and help reduce the $350 billion wasted each year on poorly-targeted medicines.
We empower researchers with the innovative tools and analytics to research and develop tomorrow’s therapeutics.
We drive productivity for the biopharmaceutical industry and help create manufacturing capacity in under-served markets.
We enable increasingly accurate diagnoses by providing advanced in vivo imaging agents & in vitro diagnostics.
We are helping create the future of regenerative medicine and cell therapy with customers by providing novel tools, technologies and methods.
We work on the things that matter to become trusted partners with our customers, combining our deep expertise, integrity, and heritage in diagnostics and biotechnology with an extensive global network and strength in infrastructure and services.
We are a $4.0 billion business of GE Healthcare serving researchers, pharmaceutical companies, and clinicians.
The Story: GE Healthcare Life Sciences
295 articles with GE Healthcare
GE Healthcare partners with Wego to provide locally manufactured single-use consumables for bioprocessing in China
CHI Franciscan Partners with GE Healthcare to Bring First AI-Powered Hospital Mission Control Center to Washington State
Advanced Analytics Software Platform Will Enhance Patient Safety, Speed Delivery of Care, and Support Quality Outcomes
Cobra Biologics, GE Healthcare and Centre for Process Innovation Collaborate to Advance Gene Therapy
Innovate UK funded project supports development of scalable, cost effective production of regenerative medicines
CRISPR pioneer Jennifer Doudna has set up shop in San Francisco’s Gladstone Institutes. Doudna, a UC Berkley professor credited with the co-discovery of CRISPR-Cas9 genome editing technique, will focus on the development of new ways to implement the gene-editing technique for disease treatment.
Swedish biotech BioLamina relies on Testa Center to expand.
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule compound technologies, today announced that the Board of Directors has appointed Jim Scully as interim chief executive officer.
GE Healthcare and Lantheus Announce Start of a Phase 3 Clinical Trial of Flurpiridaz, an Investigational Agent Being Evaluated for the Detection of Coronary Artery Disease
GE Healthcare and Lantheus Holdings, Inc. (NASDAQ: LNTH), have started a second Phase 3 clinical trial of Flurpiridaz.
GE Healthcare will be spun off from General Electric (GE) within the next 12 to 18 months. It will likely be based in Chicago, where its global headquarters are located.
The medical device market was about $521.2 billion last year and is projected to hit $674.5 billion by 2022. Here’s a look at the top 10 medical device companies in the world this year.
GE Healthcare will provide Xiangxue Pharmaceutical Co., Ltd. (XPH) with a FlexFactory™.
Tampa General Hospital (TGH) and GE Healthcare are partnering to advance care coordination, help enhance patient safety and quality, and improve efficiency with a new care coordination center.
MaxQ-AI Receives CE Mark Approval for Accipio™Ix Intracranial Hemorrhage Artificial Intelligence Software Platform
MaxQ Artificial Intelligence (MaxQ-AI), a global artificial intelligence (AI) healthcare company, today announced that it has received the CE Mark approval for its revolutionary Accipio software platform.
Annual report found market share changed as players dropped out.
All that is lacking from the likely drama surrounding patent battles over CRISPR technology in the U.S. Court of Appeals today is Michael Buffer’s cry of “Let’s get ready to rumble.”
Here is a look at the life science companies viewed as the most innovative in the world.
There are more than 900 regenerative medicine trials underway globally, including trials in cell and gene therapy, a 19 percent increase since 2016
GE, Roche Enter Partnership to Develop Integrated Digital Diagnostics Platform to Improve Oncology and Critical Care Treatment
The partnership will initially focus on products that accelerate and improve individualized treatment options for cancer and critical care patients.
Check-Cap will supply GE with supporting calibration and final assembly methodology and equipment.
Drawbridge Health to simplify the collection and transport of blood samples.
RiboBio and GE Healthcare Enter Into a Strategic Partnership for Oligonucleotide Drug Development and Manufacturing
At the 5th CNAF in Guangzhou, China, Guangzhou RiboBio and GE Healthcare Life Sciences held a strategic partnership signing ceremony.